The invention relates to an engineered glomerular endothelial cell comprising a
reduction in expression of a human leukocyte antigen and its use in an in vitro method for
determining the likelihood of occurrence of a non-HLA antibody mediated rejection against a
renal allograft in an individual in need thereof. The inventors have observed that by
suppressing expression of HLA class I and II molecules it was possible to obtain a cell able to
bind non-HLA antibodies. The in vitro diagnostic method has been validated on a cohort of
patients.